The Tumor Necrosis Factor Receptor Superfamily Member 16 pipeline drugs market research report outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 16 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tumor Necrosis Factor Receptor Superfamily Member 16 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System, Ophthalmology, Dermatology, and Toxicology which include the indications Alzheimer’s Disease, Traumatic Brain Injury, Unspecified Ophthalmological Disorders, Retinitis Pigmentosa (Retinitis), Diabetic Neuropathic Foot Ulcers, and Chemotherapy Induced Peripheral Neuropathy. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 16 targeted therapeutics development with respective active and dormant or discontinued products.
The Tumor Necrosis Factor Receptor Superfamily Member 16 pipeline targets constitutes close to nine molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, IND/ CTA Filed, Preclinical, and Discovery stages are 1, 4, 1, 2, and 1 respectively.
Tumor Necrosis Factor Receptor Superfamily Member 16 overview
Tumor necrosis factor receptor superfamily member 16 plays a role in the regulation of the translocation of GLUT4 to the cell surface in adipocytes and skeletal muscle cells in response to insulin, probably by regulating RAB31 activity, and thereby contributes to the regulation of insulin-dependent glucose uptake. Low affinity receptor which can bind to NGF, BDNF, NT-3, and NT-4.
For a complete picture of Tumor Necrosis Factor Receptor Superfamily Member 16’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
